A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer

Background: This analysis was conducted to evaluate the efficacy and safety of crizotinib based regimens intreating Chinese patients with EML4-ALK positive non-small-cell lung cancer. Materials and
Methods: Clinicalstudies evaluating the efficacy and safety of crizotinib based regimens on response and safety for Chinese patientswith EML4-ALK positive non-small-cell lung cancer were identified by using a predefined search strategy.Pooled response rate (RR) of treatment were calculated.
Results: In crizotinib based regimens, 3 clinical studieswhich including 128 Chinese patients with EML4-ALK positive non-small-cell lung cancer and treated withcrizotinib based regimen were considered eligible for inclusion. Pooled analysis suggested that, in all patients,the pooled RR was 59.3% (76/128) in crizotinib based regimens. ALT/AST mild visual disturbances, nausea, andvomiting were the main side effects. No treatment related death occurred in these crizotinib based treatments.
Conclusions: This pooled analysis suggests that crizotinib based regimens are associated with good responserate and accepted toxicities in treating Chinese patients with EML4-ALK positive non-small-cell lung cancer.